Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omalizumab, an antibody targeting IgE.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tralokinumab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lebrikizumab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dupilumab, an antibody targeting IL-4RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nemolizumab, an antibody targeting IL-31RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Spesolimab, an antibody targeting IL-36R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clesrovimab, an antibody targeting RSV F protein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bimekizumab, an antibody targeting IL-17A/IL-17F.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brodalumab, an antibody targeting IL-17RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ixekizumab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Secukinumab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brazikumab, an antibody targeting IL-23.